Hepatitis C

New Gilead hep C combo Epclusa gains FDA approval

Regulus off by more than half on FDA clinical trial hold for lead in hep C

Regulus nabs $30M in debt to keep plugging at microRNA-targeting hep C candidate

New Gilead hep C combo Epclusa gains CHMP green light

AbbVie looks to battle Gilead with new hep C data

Gilead plots broader expansion at Foster City hometown